Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

A Randomized Placebo-Controlled Phase II Trial Comparing Gemcitabine Monotherapy to Gemcitabine in Combination With AZD 1775 (MK 1775) in Women With Recurrent, Platinum Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT02101775
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-25T22:27:58.688216+00:00
Published At
2023-09-08T00:00:00+00:00
Record Updated At
2026-04-13
Results Posted At
2023-09-08
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Ovarian Brenner Tumor", "Ovarian Clear Cell Cystadenocarcinoma", "Ovarian Endometrioid Adenocarcinoma", "Ovarian Malignant Mixed Mesodermal (Mullerian) Tumor", "Ovarian Mucinous Cystadenocarcinoma", "Ovarian Seromucinous Carcinoma", "Ovarian Serous Cystadenocarcinoma", "Ovarian Serous Surface Papillary Adenocarcinoma", "Ovarian Undifferentiated Carcinoma", "Recurrent Fallopian Tube Carcinoma", "Recurrent Ovarian Carcinoma", "Recurrent Primary Peritoneal Carcinoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2026-04-13"
protocolSection.identificationModule.nctId
"NCT02101775"
protocolSection.identificationModule.officialTitle
"A Randomized Placebo-Controlled Phase II Trial Comparing Gemcitabine Monotherapy to Gemcitabine in Combination With AZD 1775 (MK 1775) in Women With Recurrent, Platinum Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers"
protocolSection.statusModule.overallStatus
"ACTIVE_NOT_RECRUITING"
protocolSection.designModule.phases
["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
"2023-09-08"

Study condition terms

  • Ovarian Brenner Tumor (protocolSection.conditionsModule.conditions)
  • Ovarian Clear Cell Cystadenocarcinoma (protocolSection.conditionsModule.conditions)
  • Ovarian Endometrioid Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Ovarian Malignant Mixed Mesodermal (Mullerian) Tumor (protocolSection.conditionsModule.conditions)
  • Ovarian Mucinous Cystadenocarcinoma (protocolSection.conditionsModule.conditions)
  • Ovarian Seromucinous Carcinoma (protocolSection.conditionsModule.conditions)
  • Ovarian Serous Cystadenocarcinoma (protocolSection.conditionsModule.conditions)
  • Ovarian Serous Surface Papillary Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Ovarian Undifferentiated Carcinoma (protocolSection.conditionsModule.conditions)
  • Recurrent Fallopian Tube Carcinoma (protocolSection.conditionsModule.conditions)
  • Recurrent Ovarian Carcinoma (protocolSection.conditionsModule.conditions)
  • Recurrent Primary Peritoneal Carcinoma (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.